MX9700538A - Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares. - Google Patents

Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.

Info

Publication number
MX9700538A
MX9700538A MX9700538A MX9700538A MX9700538A MX 9700538 A MX9700538 A MX 9700538A MX 9700538 A MX9700538 A MX 9700538A MX 9700538 A MX9700538 A MX 9700538A MX 9700538 A MX9700538 A MX 9700538A
Authority
MX
Mexico
Prior art keywords
remedies
preparation
pharmaceutically acceptable
acceptable salts
cardiovascular diseases
Prior art date
Application number
MX9700538A
Other languages
English (en)
Inventor
Roland Loser
Michael Schliack
David D Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9700538A publication Critical patent/MX9700538A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

El uso de droloxifeno o una de sus sales farmacéuticamente aceptables en la preparacion de remedios para el tratamiento de enfermedades cardiovasculares.
MX9700538A 1994-07-19 1995-05-26 Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares. MX9700538A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/276,969 US5441986A (en) 1994-07-19 1994-07-19 Estrogen agonists as remedies for prostate and cardiovascular diseases
PCT/IB1995/000403 WO1996002242A1 (en) 1994-07-19 1995-05-26 Use of droloxifene for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
MX9700538A true MX9700538A (es) 1997-04-30

Family

ID=23058874

Family Applications (2)

Application Number Title Priority Date Filing Date
MX9700534A MX9700534A (es) 1994-07-19 1995-05-26 Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
MX9700538A MX9700538A (es) 1994-07-19 1995-05-26 Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX9700534A MX9700534A (es) 1994-07-19 1995-05-26 Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.

Country Status (16)

Country Link
US (4) US5441986A (es)
EP (3) EP1029540A3 (es)
JP (2) JPH09507859A (es)
KR (2) KR100212352B1 (es)
CN (2) CN1152868A (es)
AU (2) AU689257B2 (es)
CA (2) CA2195213C (es)
FI (2) FI970214A0 (es)
HU (2) HUT77392A (es)
IL (2) IL114585A (es)
MX (2) MX9700534A (es)
MY (1) MY113079A (es)
NZ (2) NZ285158A (es)
TW (1) TW403649B (es)
WO (2) WO1996002242A1 (es)
ZA (2) ZA955963B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
US5726207A (en) * 1996-02-28 1998-03-10 Pfizer Inc. Protection of ischemic myocardium against reperfusion damage
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5733937A (en) * 1996-02-28 1998-03-31 Pfizer Inc. Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
FI982733L (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
AU5957500A (en) * 1999-07-06 2001-01-22 Endorecherche Inc. Methods of treating and/or suppressing weight gain
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040248989A1 (en) * 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
CA2652783C (en) * 2006-05-22 2015-07-14 Hormos Medical Ltd. Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis
KR101510646B1 (ko) * 2007-02-14 2015-04-10 호르모스 메디칼 리미티드 치료적으로 유용한 트리페닐부텐 유도체의 제조 방법
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
EP2909164A1 (en) 2012-10-19 2015-08-26 Fermion Oy A process for the preparation of ospemifene

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
FR2619383B1 (fr) * 1987-08-12 1989-12-08 Inst Vaisseaux Sang Proteine a activite vasculaire, derivee des monocytes et ses analogues, procede pour son extraction et leurs utilisations en therapeutique et pour la preparation d'anticorps
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
DE4401554A1 (de) * 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases

Also Published As

Publication number Publication date
CN1076967C (zh) 2002-01-02
ZA955963B (en) 1997-01-20
IL114585A0 (en) 1995-11-27
IL114585A (en) 2000-01-31
CN1152868A (zh) 1997-06-25
JPH09507859A (ja) 1997-08-12
US5852059A (en) 1998-12-22
CN1153473A (zh) 1997-07-02
EP0769941A1 (en) 1997-05-02
US5902830A (en) 1999-05-11
EP1029540A3 (en) 2001-05-16
NZ285158A (en) 2000-07-28
WO1996002242A1 (en) 1996-02-01
NZ285159A (en) 2000-10-27
KR100212352B1 (ko) 1999-08-02
JP2930424B2 (ja) 1999-08-03
IL114586A0 (en) 1995-11-27
CA2195213A1 (en) 1996-02-01
AU2417095A (en) 1996-02-16
TW403649B (en) 2000-09-01
AU2416995A (en) 1996-02-16
FI970214A7 (fi) 1997-01-17
IL114586A (en) 2000-06-29
FI970214L (fi) 1997-01-17
AU694220B2 (en) 1998-07-16
HUT77391A (hu) 1998-04-28
HK1000697A1 (en) 2002-05-10
WO1996002243A1 (en) 1996-02-01
FI970215L (fi) 1997-01-17
AU689257B2 (en) 1998-03-26
JPH09507860A (ja) 1997-08-12
CA2195093C (en) 2000-03-07
US5827892A (en) 1998-10-27
US5441986A (en) 1995-08-15
HUT77392A (hu) 1998-04-28
HU9700162D0 (en) 1997-03-28
MX9700534A (es) 1997-04-30
KR100221854B1 (ko) 1999-09-15
KR970704430A (ko) 1997-09-06
FI970215A7 (fi) 1997-01-17
CA2195213C (en) 2000-03-14
HU9700163D0 (en) 1997-03-28
ZA955964B (en) 1997-01-20
EP0771194A1 (en) 1997-05-07
CA2195093A1 (en) 1996-02-01
FI970215A0 (fi) 1997-01-17
EP1029540A2 (en) 2000-08-23
FI970214A0 (fi) 1997-01-17
KR970704429A (ko) 1997-09-06
MY113079A (en) 2001-11-30

Similar Documents

Publication Publication Date Title
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
ES2152222T3 (es) Sulfonamidas, su preparacion y su uso como medicamento e intermedio.
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
MX9202436A (es) Composiciones para el cuidado del cabello y metodo para su preparacion.
ES2136247T3 (es) Formas de dosificacion oral de azitromicina que no muestran un efecto alimento adverso.
DK0574457T3 (da) Antiviral nucleosidkombination
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
ES2080307T3 (es) Composiciones farmaceuticas.
FI954580A7 (fi) HIV-proteaasin estäjiä farmaseuttisissa yhdistelmissä käytettäväksi AIDSin hoitoon
ES2177695T3 (es) Uso de derivados funcionales de la molecual de adhesion intercelular icam-1 en terapia antiviral.
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
RU95106680A (ru) Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции
EE05099B1 (et) Bradkardiaalsete toimeainete kasutamine hpertroofiaga seotud mokardiaalsete haiguste ravimiseks ja ravimikombinatsioonid
NO960775D0 (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
ES2171550T3 (es) Utilizacion de la 2,4-diaminopirimidina 3-oxido o de una de sus sales en el tratamiento de los desordenes de la maduracion y de la estructuracion del colageno.
ITMI912509A1 (it) Uso della nimesulide nel trattamento della cataratta
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
ITRM960396A0 (it) Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali.
FI922428A0 (fi) Nya 2-amino-5-cyan-1,4- dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
SE0001916D0 (sv) Novel formulation
ES2191206T3 (es) Nueva utilizacion de la creatina.
ITMI910658A0 (it) N-(4,5-diidrossi-e 4,5,8-triidrossi-9,10-diidro-9,10-diosso-2- antracen-il)carbonil) amminoacidi utilizzabili nella terapia delle affezioni osteoarticolari
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
FI956353L (fi) Farmaseuttiset valmisteet ja niiden käyttö etenkin neurodegeneratiivisten sairauksien hoidossa